Skip to main content

Table 3 Local tumor response 1, 3 and 6 months after DEB-TACE procedure

From: Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma

Response

1 month

3 months

6 months

Complete response

7 (28.0%)

6 (28.6%)

6 (28.6%)

Partial response

11 (44.0%)

6 (28.6%)

4 (19.0%)

Stable disease

6 (24.0%)

6 (28.6%)

4 (19.0%)

Progressive disease

1 (4.0%)

3 (14.3%)

7 (33.3%)

Overall response rate

18 (72.0%)

12 (57.1%)

10 (47.6%)

Disease control rate

24 (96.0%)

18 (85.7%)

14 (66.7%)